newsfilter
← Earnings
Earnings Releases·

DataMEDS AI — Third Quarter 2026 Earnings Summary

  • Revenue increased 50% sequentially to $2.7 million in Q3 2026, driven by Corexa Pharmacy, while net income swung to a $10.5 million profit from a $34.3 million loss in the prior year period, largely due to a $19.1 million gain on debt extinguishment and reduced G&A expenses.
  • Strategic growth initiatives include the September acquisition of Helomics Corporation for cancer diagnostics, the launch of the "Health Lives Here" app for GLP-1 dispensing, and an exclusive REBOOT GLP-1 platform license, with management expecting continued revenue growth in Q4 2026.
  • The company expects to execute definitive agreements for an HMO relationship in Q4 2026, following an MOU to deploy its app to over 25,000 members, while Humana's Medicaid coverage policy for the ChemoFx® Assay opens the cancer pharmaceuticals market.
  • Financial stability improved with cash and cash equivalents rising to $476,598 and total stockholders' equity reaching $171,695 from a prior deficit, alongside the full restoration of Nasdaq listing compliance in October 2026.
Company
DATAMEDS AI INC
Sector
Consumer Defensive
Industry
Pharmaceutical Retailers